Mdluli K, Sherman D R, Hickey M J, Kreiswirth B N, Morris S, Stover C K, Barry C E
Tuberculosis Research Unit, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, Montana 59840, USA.
J Infect Dis. 1996 Nov;174(5):1085-90. doi: 10.1093/infdis/174.5.1085.
An examination of the pattern of lipid biosynthetic responses to isoniazid (INH) treatment of Mycobacterium tuberculosis and Mycobacterium smegmatis suggests that the mode of action of activated INH differs between these 2 organisms. Transformation of M. smegmatis with inhA on a plasmid construct conferred high-level resistance to INH, while the same construct failed to confer resistance upon M. tuberculosis. The inhA region from 2 clinical isolates whose resistance has been attributed to changes in the upstream promoter region has been cloned and was not sufficient to impart INH resistance to the level of the parent strain on sensitive M. tuberculosis. These putative mutant promoter elements appear to elevate expression levels of gene fusion reporter constructs, suggesting some noncausal connection between the observed mutations and the lipid metabolism of drug-resistant organisms. These results suggest that InhA is not the major target for activated INH in M. tuberculosis.
对结核分枝杆菌和耻垢分枝杆菌进行异烟肼(INH)治疗时脂质生物合成反应模式的研究表明,活化的INH在这两种生物体中的作用方式有所不同。用携带inhA的质粒构建体转化耻垢分枝杆菌可赋予其对INH的高水平抗性,而相同的构建体对结核分枝杆菌却未能赋予抗性。已克隆了来自2个临床分离株的inhA区域,其抗性归因于上游启动子区域的变化,但这不足以使敏感的结核分枝杆菌对INH的抗性达到亲本菌株的水平。这些假定的突变启动子元件似乎提高了基因融合报告构建体的表达水平,表明观察到的突变与耐药生物体的脂质代谢之间存在一些非因果关系。这些结果表明,InhA不是活化的INH在结核分枝杆菌中的主要靶点。